Meeting
2023 ASCO Annual Meeting
Preclinical evaluation of targeting PRAME with TCR mimic CAR T cells in AML.
Authors
Danielle Kirkey
Fred Hutchinson Cancer Center, Seattle, WA
Danielle Kirkey , Leila Robinson , Tiffany Hylkema , Anisha Loeb , Sommer Castro , Thao Tang , Rhonda E Ries , Cyd McKay , Christina Root , Laura Pardo , Keith Loeb , Quy Le , Soheil Meshinchi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Cellular Immmunotherapy
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 2553)
DOI
10.1200/JCO.2023.41.16_suppl.2553
Abstract #
2553
Poster Bd #
395
Abstract Disclosures
Similar Posters
Poster
2016 Genitourinary Cancers Symposium
Inducible MyD88/CD40 to allow rimiducid-dependent activation for control of proliferation and survival of chimeric antigen receptor (CAR) T cells targeting prostate stem cell antigen (PSCA).
First Author: Kevin Mark Slawin
Poster
2015 ASCO Annual Meeting
UCART19, an allogeneic “off-the-shelf” adoptive T-cell immunotherapy against CD19+ B-cell leukemias.
First Author: Julianne Smith
Poster
2024 ASCO Genitourinary Cancers Symposium
Mechanisms and strategies to overcome resistance to enfortumab vedotin in bladder cancer.
First Author: Kevin Chang
Poster
2023 ASCO Annual Meeting
Phase 1b multicenter study to evaluate CHM 1101 in patients with recurrent or progressive glioblastoma.
First Author: Jason Blair Litten